Solid oxide fuel cell and stack configuration

Details for Australian Patent Application No. 2006330504 (hide)

Owner UT-Battelle, LLC

Inventors Armstrong, Timothy; Trammell, Michael P.; Marasco, Joseph A.

Agent Collison & Co

Pub. Number AU-A-2006330504

PCT Pub. Number WO2007/076440

Priority 11/314,111 21.12.05 US

Filing date 21 December 2006

Wipo publication date 5 July 2007

International Classifications

H01M 8/24 (2006.01) Fuel cells - Grouping of fuel cells into batteries, e.g. modules

H01M 8/02 (2006.01) Fuel cells - Details

H01M 8/12 (2006.01) Fuel cells - operating at high temperature, e.g. with stabilised ZrO electrolyte

Event Publications

10 July 2008 PCT application entered the National Phase

  PCT publication WO2007/076440 Priority application(s): WO2007/076440

27 May 2010 Assignment before Grant

  UT-Battelle, LLC The application has been assigned to Worldwide Energy Inc. 2007

1 July 2010 Corrigenda

  Assignments Before Grant, Section 113 - 2006 Under the name Worldwide Energy Inc., Application No. 2006330504, under INID (71) correct the applicant name to Worldwide Energy, Inc. of Delaware

19 July 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006330508-Improved oral compositions comprising zinc citrate and/or tocopherol agents

2006330501-C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H